Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis
Fuente:
Wiley Open Access
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Publié: |
Wiley
2025
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1867005202334220288 |
|---|---|
| author | Eileen Galvani Jeffrey A. Cohen John T. Martin Kunio Nakamura Amy Kunchok Rachel Galioto |
| author_facet | Eileen Galvani Jeffrey A. Cohen John T. Martin Kunio Nakamura Amy Kunchok Rachel Galioto Eileen Galvani Jeffrey A. Cohen John T. Martin Kunio Nakamura Amy Kunchok Rachel Galioto |
| collection | Wiley Open Access |
| contents | Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis Eileen Galvani Jeffrey A. Cohen John T. Martin Kunio Nakamura Amy Kunchok Rachel Galioto Brain and Behavior ABSTRACTBackgroundLittle is known about cognitive outcomes in people with myelin oligodendrocyte glycoprotein‐IgG associated disease (pwMOGAD). While there are similarities between MOGAD and multiple sclerosis (MS), further evaluation is needed to establish the distinct cognitive trajectories for each disease.MethodsRetrospective review of subjective cognitive changes was performed for adult pwMOGAD. Subsets of pwMOGAD completed a cognitive screening measure and/or comprehensive neuropsychological testing. Their performance was compared to age, sex, and race matched people with MS (pwMS; 3:1 ratio).ResultsApproximately half (51.6%) of pwMOGAD (n = 63) endorsed cognitive dysfunction. On a cognitive screening measure (Processing Speed Test [PST]), performance did not statistically differ between pwMOGAD (n = 36; M = −0.06, SD = 1.36) and pwMS (n = 108; M = −0.04, SD = 1.30), t(62.35) = 0.18, p = 0.86. Of the pwMOGAD who completed neuropsychological testing (total n = 14), 57% demonstrated cognitive impairment on at least one test, and 36% demonstrated impairment on two or more tests. These rates did not differ from pwMS. In pwMOGAD, deficits were most common in processing speed (38.5%) and verbal fluency, spatial judgment, and immediate list recall (14.3% each). PwMOGAD performed better than pwMS on measures of visuomotor processing speed (β = −0.378, t = −2.68, p = 0.01) and cognitive flexibility (β = −0.33, t = −2.27, p = 0.03) after controlling for age, sex, race, education, and disease duration.ConclusionsSubjective cognitive complaints and objective cognitive deficits were common among pwMOGAD. Approximately one‐third of pwMOGAD demonstrated clinically significant cognitive impairment (2+ tests impaired) and individual level deficits were most common on measures of processing speed, verbal fluency, spatial judgment, and word list recall. 10.1002/brb3.70310 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1002/brb3.70310 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_brb3_70310 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis Eileen Galvani Jeffrey A. Cohen John T. Martin Kunio Nakamura Amy Kunchok Rachel Galioto Brain and Behavior Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis Eileen Galvani Jeffrey A. Cohen John T. Martin Kunio Nakamura Amy Kunchok Rachel Galioto Brain and Behavior ABSTRACTBackgroundLittle is known about cognitive outcomes in people with myelin oligodendrocyte glycoprotein‐IgG associated disease (pwMOGAD). While there are similarities between MOGAD and multiple sclerosis (MS), further evaluation is needed to establish the distinct cognitive trajectories for each disease.MethodsRetrospective review of subjective cognitive changes was performed for adult pwMOGAD. Subsets of pwMOGAD completed a cognitive screening measure and/or comprehensive neuropsychological testing. Their performance was compared to age, sex, and race matched people with MS (pwMS; 3:1 ratio).ResultsApproximately half (51.6%) of pwMOGAD (n = 63) endorsed cognitive dysfunction. On a cognitive screening measure (Processing Speed Test [PST]), performance did not statistically differ between pwMOGAD (n = 36; M = −0.06, SD = 1.36) and pwMS (n = 108; M = −0.04, SD = 1.30), t(62.35) = 0.18, p = 0.86. Of the pwMOGAD who completed neuropsychological testing (total n = 14), 57% demonstrated cognitive impairment on at least one test, and 36% demonstrated impairment on two or more tests. These rates did not differ from pwMS. In pwMOGAD, deficits were most common in processing speed (38.5%) and verbal fluency, spatial judgment, and immediate list recall (14.3% each). PwMOGAD performed better than pwMS on measures of visuomotor processing speed (β = −0.378, t = −2.68, p = 0.01) and cognitive flexibility (β = −0.33, t = −2.27, p = 0.03) after controlling for age, sex, race, education, and disease duration.ConclusionsSubjective cognitive complaints and objective cognitive deficits were common among pwMOGAD. Approximately one‐third of pwMOGAD demonstrated clinically significant cognitive impairment (2+ tests impaired) and individual level deficits were most common on measures of processing speed, verbal fluency, spatial judgment, and word list recall. 10.1002/brb3.70310 http://creativecommons.org/licenses/by/4.0/ |
| title | Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis |
| topic | Brain and Behavior |
| url | https://onlinelibrary.wiley.com/doi/10.1002/brb3.70310 |